Why even good pharma names can fail

A strong pharmaceutical name is not the one everyone likes in the first meeting. It is the one that survives the process.

In pharmaceutical naming, the strongest name is not always the first favourite. It is the name that survives review.

Many pharmaceutical names start with enthusiasm.A shortlist is presented. One name feels right. It sounds modern, distinctive and relevant. The internal team likes it. Marketing likes it. Sometimes even senior management becomes attached to it.

And then, much later in the process, the name fails.

This is one of the most frustrating situations in pharmaceutical naming. Not because the name was weak. Often, it was creatively strong. It failed because pharmaceutical naming is not just a creative exercise. It is a regulatory, linguistic, legal and safety-sensitive process.

A good name must do more than sound appealing. It must be defendable.

The late-stage naming problem

Names usually fail late for predictable reasons.

They may be too close to an existing medicine. They may create a look-alike or sound-alike risk. They may suggest an unapproved benefit. They may conflict with INN or USAN conventions. They may have an unfortunate meaning in another language. They may be difficult to pronounce in important markets. Or they may simply be too weak from a trademark perspective.

The problem is that many of these risks are not visible during a first creative presentation.

At that stage, people often respond emotionally. They ask:Do we like it?Does it sound pharmaceutical?Does it fit the brand story?

Those are relevant questions. But they are not enough.

The EMA’s review of invented names is part of its safety evaluation within the authorisation procedure, because proposed names can create risks of confusion or medication error.  The FDA also describes best practices for developing proprietary names specifically to help minimise name-related medication errors.

That means a name is never judged only as a brand asset. It is judged as part of the medication-use system.

Why internal favourites are dangerous

Every naming project has favourites. That is normal. A name can feel elegant, powerful or strategically perfect.

But internal preference can become a risk when it appears too early. Once a team falls in love with a name, it becomes harder to assess it objectively. Warning signs may be explained away. Similarities may be underestimated. Linguistic issues may be treated as minor. Regulatory concerns may be postponed.

This is how naming projects lose time.

The favourite name becomes the emotional benchmark, while safer and stronger alternatives are undervalued. By the time the risk becomes undeniable, the project may already be close to submission, launch planning or packaging development.

Late failure is rarely caused by one dramatic mistake. It is usually caused by small risks that were not taken seriously early enough.

The name must survive several worlds

A pharmaceutical name has to perform in many environments at once.

• It must work in strategy.

• it must work in speech.

• It must work in writing.

• It must work on packaging.

• It must work across markets.

• It must work in trademark screening.

• It must work under regulatory review.

• And most importantly, it must not create avoidable risk for healthcare professionals or patients.

This is what makes pharma naming different from ordinary brand naming.

In consumer branding, a surprising or provocative name can be an advantage. In pharma, a name that is too clever may become a liability. A name that communicates too directly may be seen as promotional or misleading. A name that is distinctive in one country may create problems in another.

The best pharma names are often not the loudest names. They are the names that remain strong after testing, screening and regulatory review.

Start with survival, not preference

At Readge, we believe the strongest naming process starts with the end in mind.

That means developing names that are creative, but also built for scrutiny. It means combining brand strategy with regulatory awareness from the beginning. It means testing names before teams become too attached to them. It means looking at pronunciation, differentiation, linguistic suitability, trademark position and safety risk as part of one integrated process.

A name should not only be liked. It should be prepared.

Because in pharmaceutical naming, success is not winning the first meeting. Success is reaching the market with a name that is distinctive, relevant, compliant and safe.

Good pharma names do not simply sound good.

They survive.

Michael Dijkstra Taurel / michael@readge.com